Morgan Stanley dropped price target and Cantor Fitzgerald reduced price target on Regeneron Pharmaceuticals stock.
5 reports, 1 independent
Updated Nov 2
Gone quiet
- Reports
- 5
- Developments
- 2
- Repetition
- 60%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley dropped price target and Cantor Fitzgerald reduced price target on Regeneron Pharmaceuticals stock.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Multiple firms raised price targets and boosted ratings for Regeneron Pharmaceuticals.1 source
Morgan Stanley dropped price target and Cantor Fitzgerald reduced price target on Regeneron shares.1 source
Keep exploring
The entities involved
-
Regeneron Pharmaceuticals
American pharmaceutical company
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald, Citigroup, and MarketBeat issued rating updates and price targets for Rigel Pharmaceuticals, Inc.
- MarketBeat provided consensus ratings while Cantor Fitzgerald and Jefferies Financial Group issued rating updates for Primoris Services Corporation.
- Multiple financial firms, including Raymond James, Wells Fargo, UBS, Cantor Fitzgerald, and KeyCorp, issued rating updates and target price changes on November 2, 2026.
- Truist Financial and Cantor Fitzgerald set and raised target prices for Broadstone Net Lease.
- Morgan Stanley dropped its target price on Lowe's shares, with Benzinga and MarketBeat reporting the change.